Last reviewed · How we verify

NCT06003985

Gastric Ultrasound Assessment for Patients Taking GLP1 Agonists

Completed Last updated 26 November 2025
What this trial tests

trial testing Gastric Ultrasound Exam in Gastric Ultrasound in 354 participants. Completed in 1 February 2025.

Timeline
29 August 2023
Primary endpoint
31 January 2025
1 February 2025

Quick facts

Lead sponsorHospital for Special Surgery, New York
StatusCompleted
Study typeOBSERVATIONAL
Enrollment354
Start date29 August 2023
Primary completion31 January 2025
Estimated completion1 February 2025
Sites8 locations across Canada, United States

Drugs / interventions tested

Conditions studied

Sponsor

Hospital for Special Surgery, New York

Who can join

Adults 18 to 99, any sex, with Gastric Ultrasound or Glucagon-like Peptide 1. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to perform bedside gastric point of care ultrasound (POCUS) exams to assess the gastric volume and content (clear liquids vs solid food) perioperatively in patients who take glucagon-like peptide 1 (GLP-1) agonist medications compared to patients who do not take GLP-1 agonists.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Gastric Ultrasound Exam

Trials testing the same drug.

Other recruiting trials for Gastric Ultrasound

Currently open trials in the same condition.

Other Hospital for Special Surgery, New York trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06003985.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing